Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Mountainside Hospital
mi
from
Morristown, NJ
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Mountainside Hospital
mi
from
Morristown, NJ
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Columbia Medical University
mi
from
New York, NY
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Columbia Medical University
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
University of North Carolina at Chapel Hill School of Medicine
mi
from
Chapel Hill, NC
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
University of North Carolina at Chapel Hill School of Medicine
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Wake Forest University School of Medicine
mi
from
Winston Salem, NC
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Wake Forest University School of Medicine
mi
from
Winston Salem, NC
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Gabrail Cancer Center
mi
from
Canton, OH
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Barrett Cancer Center
mi
from
Cincinnati, OH
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Barrett Cancer Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Cleveland Clinic Foundation, Taussig Cancer Center
mi
from
Cleveland, OH
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Cleveland Clinic Foundation, Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
University of Texas - MD Anderson
mi
from
Houston, TX
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
University of Texas - MD Anderson
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Texas Oncology - Allison Cancer Center
mi
from
Midland, TX
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Texas Oncology - Allison Cancer Center
mi
from
Midland, TX
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated:  11/12/2015
Cross Cancer Institute
mi
from
Edmonton,
Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma
A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment With OncoVEX^GM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients With Unresectable Stage IIIb, IIIc and IV Disease
Status: Enrolling
Updated: 11/12/2015
Cross Cancer Institute
mi
from
Edmonton,
Click here to add this to my saved trials
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated:  11/12/2015
UCSD Cancer Center, Thornton Hospital
mi
from
La Jolla, CA
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated: 11/12/2015
UCSD Cancer Center, Thornton Hospital
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated:  11/12/2015
UCLA
mi
from
Los Angeles, CA
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated: 11/12/2015
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated:  11/12/2015
University of Colorado, Anschutz Cancer Pavillion
mi
from
Aurora, CO
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated: 11/12/2015
University of Colorado, Anschutz Cancer Pavillion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated:  11/12/2015
Hubert H. Humphrey Cancer Center
mi
from
Robbinsdale, MN
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated: 11/12/2015
Hubert H. Humphrey Cancer Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated:  11/12/2015
Mountainside Hospital
mi
from
Montclair, NJ
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated: 11/12/2015
Mountainside Hospital
mi
from
Montclair, NJ
Click here to add this to my saved trials
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated:  11/12/2015
Columbia University, Department of Surgery
mi
from
New York, NY
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated: 11/12/2015
Columbia University, Department of Surgery
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated:  11/12/2015
Mary Crowely Medical Research Center
mi
from
Dallas, TX
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated: 11/12/2015
Mary Crowely Medical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated:  11/12/2015
Royal Marsden Hospital
mi
from
London,
A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma
Status: Enrolling
Updated: 11/12/2015
Royal Marsden Hospital
mi
from
London,
Click here to add this to my saved trials
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated:  11/12/2015
Rush University Medical Center
mi
from
Chicago, IL
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated: 11/12/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated:  11/12/2015
Indiana University
mi
from
Indianapolis, IN
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated: 11/12/2015
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated:  11/12/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated: 11/12/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated:  11/12/2015
James Graham Brown Cancer Center
mi
from
Louisville, KY
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated: 11/12/2015
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated:  11/12/2015
Hubert H. Humphrey Cancer Center
mi
from
Robbinsdale, MN
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated: 11/12/2015
Hubert H. Humphrey Cancer Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated:  11/12/2015
University of North Carolina at Chapel Hill School of Medicine
mi
from
Chapel Hill, NC
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated: 11/12/2015
University of North Carolina at Chapel Hill School of Medicine
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated:  11/12/2015
Mary Crowley Medical Research Center
mi
from
Dallas, TX
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated: 11/12/2015
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated:  11/12/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated: 11/12/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated:  11/12/2015
Oncology & Hematology Associates Of Southwest Virginia, Inc.
mi
from
Salem, VA
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated: 11/12/2015
Oncology & Hematology Associates Of Southwest Virginia, Inc.
mi
from
Salem, VA
Click here to add this to my saved trials
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated:  11/12/2015
Royal Marsden Hospital
mi
from
London,
An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma
An Extension Protocol to Evaluate the Efficacy and Safety of Extended Use Treatment With OncoVEX^GM-CSF for Eligible Melanoma Patients Participating in Study 005/05
Status: Enrolling
Updated: 11/12/2015
Royal Marsden Hospital
mi
from
London,
Click here to add this to my saved trials
Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion
A Parallel Phase I/II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Peginterferon Alfa-2b in Advanced Melanoma
Status: Enrolling
Updated:  11/13/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion
A Parallel Phase I/II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Peginterferon Alfa-2b in Advanced Melanoma
Status: Enrolling
Updated: 11/13/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
B-Receptor Signaling in Cardiomyopathy
B-Receptor Signaling in Cardiomyopathy
Status: Enrolling
Updated:  11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
B-Receptor Signaling in Cardiomyopathy
B-Receptor Signaling in Cardiomyopathy
Status: Enrolling
Updated: 11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Aurora, CO
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Indianapolis, IN
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Charleston, SC
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Dallas, TX
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
La Jolla, CA
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
San Francisco, CA
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Iowa City, IA
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Lebanon, NH
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Nashville, TN
A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma
A Phase I, Randomized, Open-label, Multi-center, Two Period Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of a Single Oral Dose of RO5185426, Followed by Administration of 960 mg RO5185426 Twice Daily to BRAF V600E Positive Metastatic Melanoma Patients
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain
Status: Enrolling
Updated:  11/24/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain
Status: Enrolling
Updated: 11/24/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
Phase I Study Of Hepatic Arterial Infusion Of Nab-Paclitaxel (Abraxane®) In Patients With Metastatic Melanoma In The Liver
Status: Enrolling
Updated:  11/25/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
Phase I Study Of Hepatic Arterial Infusion Of Nab-Paclitaxel (Abraxane®) In Patients With Metastatic Melanoma In The Liver
Status: Enrolling
Updated: 11/25/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
Releasing the Cancer Patient's Immune System From Down-regulation With Timed Delivery of Standard Chemotherapy
Status: Enrolling
Updated:  11/25/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
Releasing the Cancer Patient's Immune System From Down-regulation With Timed Delivery of Standard Chemotherapy
Status: Enrolling
Updated: 11/25/2015
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials